Relevant bibliographies by topics / Ketorolac

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Ketorolac'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ketorolac.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ketorolac"

1

Butcher, Belinda, Elizabeth Hutchings, Belinda Fazekas, Katherine Clark, Debra Rowett, and David Currow. "Opioid-sparing effects of ketorolac in palliative care patients receiving opioids for chronic cancer-related pain: A systematic literature review." Palliative Medicine 36, no. 1 (October 11, 2021): 71–80. http://dx.doi.org/10.1177/02692163211045310.

Full text
Abstract:
Background: Standard of care in treatment of cancer-related pain involves opioids in combination with non-steroidal anti-inflammatory drugs (NSAID). Ketorolac, a NSAID, has demonstrated opioid-sparing effects in other clinical settings. Aim: This systematic literature review investigated ketorolac’s opioid-sparing effects in patients receiving opioids for chronic, cancer-related pain. Design: The primary outcome was total daily dose of opioids. Secondary outcomes included frequency of opioid use, use and frequency of ‘rescue’ medication and adverse events. Outcomes were described, and meta-analysed where possible. PROSPERO registration CRD42019130894. Data sources: Articles included original research, from any study phase or methodology, published in English in a peer-reviewed journal or conference between 1990 and 2020; included subjects >18 years; had chronic cancer-related pain and described the use of opioid-sparing effect of ketorolac. Results: Nine articles were included. While there was significant heterogeneity, ketorolac may have an opioid-sparing effect, with significant reductions in total daily dose of morphine observed in a single randomised controlled trial (SMD −4.30 mg, 95% CI −5.36 to −3.25), but the changes in the before and after studies were not statistically significant −0.46 mg (95% CI −1.14 to 0.22). Ketorolac was associated with greater likelihood of complete pain relief, but the data were heterogeneous. Insufficient data were available to analyse frequency of opioid use, or rescue medication requirements. Conclusions: Given the heterogeneity of the data, adequately powered, randomised controlled trials are required to establish any opioid-sparing effect of ketorolac. For patients not responding to conventional pain management, ketorolac may have a role in treatment augmentation.
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 693 (March 1998): 13. http://dx.doi.org/10.2165/00128415-199806930-00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 1179 (November 2007): 21. http://dx.doi.org/10.2165/00128415-200711790-00063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 1137 (February 2007): 17. http://dx.doi.org/10.2165/00128415-200711370-00052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 1361 (July 2011): 26–27. http://dx.doi.org/10.2165/00128415-201113610-00091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 1374 (October 2011): 23. http://dx.doi.org/10.2165/00128415-201113740-00079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 536 (February 1995): 10. http://dx.doi.org/10.2165/00128415-199505360-00039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 567 (September 1995): 8. http://dx.doi.org/10.2165/00128415-199505670-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 577 (November 1995): 7. http://dx.doi.org/10.2165/00128415-199505770-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Ketorolac." Reactions Weekly &NA;, no. 585 (January 1996): 8. http://dx.doi.org/10.2165/00128415-199605850-00033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ketorolac"

1

Gallivan, Sean Thomas. "Safety of Epidurally Administered Ketorolac in Dogs." Thesis, Virginia Tech, 1999. http://hdl.handle.net/10919/33874.

Full text
Abstract:
The objective of this study was to evaluate the clinical, cerebrospinal fluid (CSF), and histopathologic effects of an epidurally administered NSAID (ketorolac) in dogs. This was performed as a blinded, placebo controlled study using twenty-two adult mixed breed dogs with 16 treatment and 6 control dogs. Dogs were anesthetized and epidural catheters were placed at the lumbosacral space. Catheter placement was evaluated fluoroscopically. Ketorolac (0.4 mg/kg) or placebo (5% ethanol) was administered epidurally over a 52 hour period, with 5 injections given at 12 hour intervals. At 1, 2, 4, or 8 hours after the first and last injection of ketorolac, dogs were anesthetized and CSF was obtained. Control dogs had CSF sampled 1 hour after the first and last ethanol injection. Neurologic function and pain response was evaluated before and during the study. Selected dogs were then euthanized and necropsies performed. None of the dogs exhibited any clinical or neurological abnormalities during the study. No statistical difference was noted in pain response or CSF analysis between treatment and control dogs. Gross necropsy revealed gastrointestinal ulceration of varying degrees in all treatment dogs. Histopathologic analysis of the spinal cord and meninges revealed minimal focal leptomeningeal phlebitis in 2 of 8 treatment dogs and minor subdural inflammation in one control dog. No changes to the neural structures were noted in any dogs. Epidural administration of ketorolac did not cause clinical signs, alteration in CSF values, or pathologic changes to the spinal cord when used for short duration. Gastrointestinal ulceration was common when ketorolac was administered epidurally at 0.4 mg/kg every 12 hours for 5 treatments. This study documented the safety of epidurally administered ketorolac in dogs before an efficacy trial can be performed. Gastrointestinal ulceration may limit use to short duration or single injection.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
2

Watts, Kathryn Teal. "An Evaluation of Intranasal Ketorolac in an Untreated Endodontic Pain Model." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1532509409975989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Brito, Fabiano Capato de 1976. "Analgesia preemptiva em cirurgias de implantes dentários = estudo comparativo com dexametasona e cetorolaco." [s.n.], 2014. http://repositorio.unicamp.br/jspui/handle/REPOSIP/290772.

Full text
Abstract:
Orientador: Eduardo Dias de Andrade
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba
Made available in DSpace on 2018-08-24T16:11:06Z (GMT). No. of bitstreams: 1 Brito_FabianoCapatode_D.pdf: 1226607 bytes, checksum: bf93752c3c24f16fc0b41670850b7e5d (MD5) Previous issue date: 2014
Resumo: A analgesia preemptiva é um regime analgésico instituído previamente ao estímulo nocivo, com o objetivo de prevenir a hiperalgesia inflamatória e o subsequente estímulo que amplifica a dor no sistema nervoso central. Para aplicá-la na clínica cirúrgica odontológica, alguns fármacos com propriedades analgésicas e anti-inflamatórias têm sido avaliados, todavia com resultados ainda conflitantes. Por este motivo, propôs-se investigar, de forma comparativa, a analgesia preemptiva com dexametasona ou cetorolaco em cirurgias implantodônticas. Para tal, foram selecionados 33 indivíduos de ambos os gêneros, ASA I, que necessitavam de reabilitação bucal por meio da instalação de implantes dentários na região posterior da maxila ou mandíbula. Por ocasião da primeira ou da segunda intervenção, os voluntários foram tratados de maneira randomizada, com uma única dose de dexametasona 4 mg (via oral) ou cetorolaco 10 mg (via sublingual), administrada uma hora antes do início da cirurgia. A analgesia preemptiva foi avaliada pelo período de tempo compreendido entre o término do procedimento cirúrgico e o momento exato da tomada do primeiro comprimido do analgésico de resgate (paracetamol 750 mg), na fase pós-operatória. Os sujeitos da pesquisa também foram orientados a expressar a presença ou não de dor, e sua intensidade, no período das primeiras 12 horas pós-operatórias, na forma de uma escala analógica visual. Os dados foram tratados estatisticamente pelo teste de Wilcoxon, com nível de significância de 5%. Considerando o tempo decorrido entre a administração dos fármacos e a tomada do primeiro comprimido de analgésico, ou não, foi possível observar que não houve diferença estatisticamente significante (Wilcoxon, p = 0,0596) entre o cetorolaco (mediana = 3,6 h) e a dexametasona (mediana = 2,75 h). Também não houve diferença na incidência e na intensidade de dor no período das primeiras 12 horas pós-operatórias, se comparados os tratamentos (p = 0,7610). Concluiu-se que a dexametasona e o cetorolaco promovem analgesia preemptiva de forma similar em cirurgias de instalação de implantes dentários
Abstract: Preemptive analgesia is an analgesic regimen instituted prior to the noxious stimulus, in order to prevent inflammatory hyperalgesia and subsequent stimulus that amplifies pain in the central nervous system. To apply it in clinical dental surgery, drugs that have analgesic and anti-inflammatory properties have been studied, but the results are still conflicting. For this reason, we proposed to investigate, in a comparative way, preemptive analgesia with dexamethasone or ketorolac in surgical installation of dental implants. To this end, we selected 33 individuals of both genders, ASA I, who needed oral rehabilitation using dental implants in the posterior maxilla or mandible. On the occasion of the first or second intervention, the volunteers were treated randomly with dexamethasone 4 mg orally or ketorolac 10 mg sublingual on a single dose one hour before the intervention. Preemptive analgesia was assessed for the period of time between the end of the surgical procedure and the exact time of taking the first tablet of analgesic rescue medication (paracetamol 750 mg) postoperatively. The subjects were also instructed to express the presence or absence of pain and its intensity within the first 12 postoperative hours in the form of a visual analog scale. The data were statistically analyzed using the Wilcoxon test, with the significance level of 5%. Considered the mean time elapsed between drug administration and the first tablet, it was observed that there was no statistically significant difference (Wilcoxon, p = 0.0596) between ketorolac (median = 3, 6 h) and dexamethasone (median = 2.75 h). There was no difference in the incidence and intensity of pain during the first 12 postoperative hours, when the treatments (p = 0.7610) were compared. It was concluded that dexamethasone and ketorolac promote preemptive analgesia in a similar manner to the installation of dental implant surgery
Doutorado
Farmacologia, Anestesiologia e Terapeutica
Doutor em Odontologia
APA, Harvard, Vancouver, ISO, and other styles
4

Balzer, Stephen. "IBUPROFEN/ACETAMINOPHEN VERSUS SPRIX IN TEETH DIAGNOSED WITH PULPAL NECROSIS AND SYMPTOMATIC APICAL PERIODONTITIS." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu153191176802337.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pasloske, Kirby Shawn. "Ketorolac pharmacokinetics and effects on neutrophil function and prostaglandin E(2) concentrations in dogs." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq24422.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Conio, Nathalie. "Efficacite antalgique de l'association de la morphine et d'un anti-inflammatoire non steroidien en postoperatoire : a propos de 42 cas." Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1MS17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Costa, ClÃber Soares Pimenta. "DeterminaÃÃo do Perfil FarmacocinÃtico do Cetorolaco de Trometamina Comprimido de 30mg administrado por Via Sublingual em VoluntÃrios SaudÃveis." Universidade Federal do CearÃ, 2011. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=5742.

Full text
Abstract:
Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico
Cetorolaco de trometamina (Cetorolaco) à um antiinflamatÃrio nÃo esteroidal (AINE) usado no tratamento da dor. O uso da formulaÃÃo sublingual tem diversas vantagens, como por exemplo, aumento da biodisponibilidade e fÃcil administraÃÃo, especialmente em pacientes que tem dificuldades para engolir. Assim, o objetivo deste estudo foi avaliar o perfil farmacocinÃtico da formulaÃÃo sublingual do Cetorolaco em voluntÃrios brasileiros do sexo masculino. Este foi um estudo aberto, nÃo randomizado, 01 perÃodo, 01 tratamento, com dose Ãnica de rÃpida absorÃÃo, em que foi administrado um comprimido de 30 mg de Cetorolaco por via sublingual. Foram incluÃdos apenas voluntÃrios brasileiros sadios. ApÃs uma noite internados, os voluntÃrios receberam uma dose Ãnica da formulaÃÃo sublingual. Amostras de plasma foram obtidas em um perÃodo de 24 horas apÃs a administraÃÃo. A concentraÃÃo plasmÃtica de Cetorolaco foi analisada por Cromatrografia LÃquida de Alta EficiÃncia acoplada a um EspectrÃmetro de Massa para anÃlise dos parÃmetros farmacocinÃticos, incluindo o Cmax, ASC0-24, e ASC0-∞. A tolerabilidade foi avaliada pelo monitoramento dos sinais vitais, resultados das anÃlises laboratoriais, anamnese e exame fÃsico com os voluntÃrios. 14 voluntÃrios do sexo masculino foram incluÃdos e completaram o estudo. Os valores dos parÃmetros farmacocinÃticos (mÃdia  desvio padrÃo, exceto mediana para o tempo do Tmax) calculados para a formulaÃÃo foram os seguintes: ASC0-∞ (9682  1908 ng*h/mL); ASC0-24 (9346  1789 ng*h/mL); Cmax (2605  465 ng/mL); Tmax (0,58  0,22 h); t1/2 (5,76  0,69 h) and Ke (0,12  0,02 1/h). A formulaÃÃo do cetorolaco foi bem tolerada na dose administrada e nenhuma reaÃÃo adversa foi observada. A vantagem do uso da formulaÃÃo sublingual de Cetorolaco à sua administraÃÃo prÃtica. Essa pode ser uma escolha para dor moderada e grave, especialmente em pacientes em que a via parenteral à indesejada ou impraticÃvel, ou para aqueles que tenham dificuldade de engolir. Os mÃtodos foram aplicados com sucesso, sendo possÃvel analisar os parÃmetros farmacocinÃticos e avaliar a seguranÃa da formulaÃÃo do comprimido de 30mg do cetorolaco de trometamina administrado por via sublingual em voluntÃrios saudÃveis.
Ketorolac tromethamine (ketorolac) is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of pain. The use of a sublingual analgesic has several advantages such as increased bioavailability and ease of administration, especially in patients who have difficulty swallowing. Thus, the aim of this study was to evaluate the pharmacokinetic profile of a formulation of ketorolac in Brazilian male volunteers. This was an open, non-randomized, 01 period, 01 treatment, single dose under fasting conditions study where was administered 30 mg sublingual tablet formulation of ketorolac. Healthy Brazilians male were eligible for inclusion. After an overnight fast, subjects received a single sublingual dose of the formulation. Plasma samples were obtained over a 24-hour period after administration. Plasma ketorolac concentrations were analyzed by High Performance Liquid Chromatography coupled Mass Spectrometry for analysis of pharmacokinetic properties, including Cmax, AUC0-24, and AUC0-∞. Tolerability was assessed by vital sign monitoring, laboratory analysis results, anamnesis and physical examination. A total of 14 male subjects were enrolled and completed the study. The pharmacokinetics parameters values (mean  standard deviation, except median for time to Tmax) calculated for formulation were as follows: AUC0-∞ (9682  1908 ng*h/mL); AUC0-24 (9346  1789 ng*h/mL); Cmax (2605  465 ng/mL); Tmax (0,58  0,22 h); t1/2 (5,76  0,69 h) and Ke (0,12  0,02 1/h). The ketorolac formulation was well tolerated at the administered dose and no adverse reactions were observed. The advantage of the use of the sublingual formulation of ketorolac is its practical administration. It can be the treatment of choice for moderate and severe pain, especially in patients where parenteral route is undesirable or impracticable, or those who have difficulty of swallowing. The methods were successfully applied, it is possible to analyze the pharmacokinetic parameters and assess the safety of the tablet formulation of 30 mg of ketorolac tromethamine administered sublingually in healthy volunteers.
APA, Harvard, Vancouver, ISO, and other styles
8

Phan, Phuc Thanh. "Analgésie morphinique contrôlée par le patient en postopératoire : intérêt de l'association avec les antalgiques non morphiniques." Montpellier 1, 1993. http://www.theses.fr/1993MON11197.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Agi, Erol Proffit William R. "Effects of local administration of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, on orthodontic tooth movement in rats." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2006. http://dc.lib.unc.edu/u?/etd,298.

Full text
Abstract:
Thesis (M.S.)--University of North Carolina at Chapel Hill, 2006.
Title from electronic title page (viewed Oct. 10, 2007). "... in partial fulfillment of the requirements for the degree of Master of Science in the Department of Orthodontics in the School of Dentistry." Discipline: Orthodontics; Department/School: Dentistry.
APA, Harvard, Vancouver, ISO, and other styles
10

Rossanezi, Gustavo. "Micropartículas biodegradáveis para liberação prolongada intraocular de cetorolaco de trometamina obtidas po Spray Drying /." Araraquara : [s.n.], 2008. http://hdl.handle.net/11449/91691.

Full text
Abstract:
Orientador: Anselmo Gomes de Oliveira
Banca: Ana Dóris de Castro
Banca: Victor Hugo Vitorino Sarmento
Resumo: As doenças que afetam o globo ocular de maneira geral têm a terapêutica limitada pela grande dificuldade de se atingir e manter níveis efetivos de fármacos nessa região. Isso porque as formas farmacêuticas convencionais para as doenças oculares são destinadas a aplicação tópica, e não proporcionam níveis terapêuticos no corpo vítreo, retina e coróide. Dessa forma, os sistemas de liberação prolongada de fármacos para aplicação intraocular representam um interesse significativo para a terapêutica em oftalmologia. Sendo assim, o presente trabalho teve como objetivo produzir através da técnica de "Spray Drying" micropartículas biodegradáveis a partir do ácido poli-láctico-co-glicólico (PLGA) contendo cetorolaco de trometamina (CETO), um antiinflamatório não-esteróide que tem apresentado resultados relevantes no tratamento pós-operatório de cirurgias oftálmicas, proporcionando maior conforto e diminuindo os efeitos colaterais causados pelos antiinflamatórios esteróides. Utilizando o método proposto foram produzidas micropartículas com diferentes proporções de CETO:PLGA. As micropartículas foram visualizadas através da Microscopia Eletrônica de Varredura (MEV), apresentando formato esférico e uniforme, com superfícies lisas, e o tamanho médio e distribuição de tamanho das partículas foram determinados através do espalhamento de luz. Somente uma das amostras foi descartada, devido a não formação de microesferas. As propriedades físico-químicas de todos os sistemas foram estudadas utilizando espectroscopia de infravermelho (IR), calometria diferencial exploratória (DSC) e termogravimetria/termogravimetria derivada. Os resultados destes estudos mostraram que após a obtenção as estruturas químicas dos componentes foram preservadas... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The diseases that affect the ocular globe generally have limited treatment due their difficulty to achieve and sustain effective levels of drugs in this region. Because conventional pharmaceutical forms for ocular diseases are destined to topical application, and not provide therapeutic levels in vitreous, retina and choroid. In this way, the ocular drug delivery systems represent a strategy for therapy in ophthalmology. Thus, the present work had as aim to produce through Spray drying technique biodegradable microparticles of poly-lactic co-glycolic acid (PLGA) containing ketorolac tromethamine (CETO), a nonsteroidal anti-inflammatory that has presented relevant results in post-operative treating of ophthalmic surgery, providing greater comfort and reducing the adverse effects caused by steroidal anti-inflammatory. Using the considered method were produced microparticles with different ratios of CETO: PLGA. The microparticles were accessed through Scanning Electronic Microscopy (SEM), presenting itself spherical and uniform, smooth surface, and the particle size analysis and mean diameter were determined by Dynamic Light Scattering. Only one non spherical sample was dismissed. The physicochemical properties of all systems were studied using infrared spectroscopy (IR), differential scanning calorimetry (DSC) and thermogrametry/ derivative thermogravimetry (TG/DTG). The results of these studies showed that after produced the chemical structure of components were preserved, only having the necessaries interactions to promote prolonged released. The amounts of encapsulated CETO were determined by UV-Vis spectrophotometry... (Complete abstract click electronic access below)
Mestre
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Ketorolac"

1

Publications, ICON Health. Ketorolac - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sutters, Kimberly Ann. ANALGESIC EFFICACY AND SAFETY OF SINGLE-DOSE INTRAMUSCULAR KETOROLAC FOR POSTOPERATIVE PAIN MANAGEMENT IN CHILDREN FOLLOWING TONSILLECTOMY. 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aina, Titilopemi A. O., and Sharon Redd. Tonsillar Bleed. Edited by Erin S. Williams, Olutoyin A. Olutoye, Catherine P. Seipel, and Titilopemi A. O. Aina. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190678333.003.0014.

Full text
Abstract:
Post-tonsillectomy hemorrhage (PTH) is a very serious complication that can occur after a tonsillectomy. There are two broad categories of PTH, based on onset of bleeding: primary (less than 24 hours) or secondary (greater than 24 hours). Primary bleeding is often attributed to the surgical technique, and secondary bleeding is attributed to sloughing of healing surgical scar. Risk factors for PTH include male gender, age greater than 70 years (in adults), age greater than 5 years (in pediatrics), recurrent tonsillitis, use of nonsteroidal anti-inflammatory drugs (particularly ketorolac), among others. Rapid-sequence induction and intubation is advised to reduce the risk of aspiration for patients presenting with PTH.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Ketorolac"

1

Peretz, Gil, Ayala Pollack, and Yoel Greenwald. "Ketorolac Tromethamine." In Encyclopedia of Ophthalmology, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-35951-4_1111-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Peretz, Gil, Ayala Polack, and Yoel Greenwald. "Ketorolac Tromethamine." In Encyclopedia of Ophthalmology, 1008–11. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-540-69000-9_1111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patel, Ankur A., Chandni Patel, Arpit Patel, Navdeep Jassal, and Ritika Oberoi-Jassal. "Ketorolac Infusion Therapy." In Infusion Therapy, 185–96. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17478-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cavanaugh, P. F. "The Use of Ketorolac Tromethamine Oral Rinse for the Treatment of Periodontitis in Adults." In Side Effects of Anti-Inflammatory Drugs IV, 317–24. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Ketorolac." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 1978–79. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/01271-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Ketorolac." In Meyler's Side Effects of Drugs, 431–33. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00948-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Ketorolac." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-948.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Ketorolac." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Papich, Mark G. "Ketorolac Tromethamine." In Saunders Handbook of Veterinary Drugs, 433–34. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00329-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Ketorolac Tromethamine." In Extended Stability for Parenteral Drugs, 232–33. American Society of Health-System Pharmacists, 2017. http://dx.doi.org/10.37573/9781585285280.109.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ketorolac"

1

Sabdowati, Rosati, Dwi Siswanta, Dadan Hermawan, and Mudasir Mudasir. "Molecular Docking Approach for Prediction of Chromatographic Chiral Separation of Ketorolac Using AGP Column." In Life Science, Materials and Applied Chemistry. Switzerland: Trans Tech Publications Ltd, 2022. http://dx.doi.org/10.4028/p-v22c3x.

Full text
Abstract:
Prediction of chiral separation of R- and S-ketorolac has been carried out using a molecular docking approach. Geometry optimization using different calculation methods suggests that Hartree-Fock (HF)/6-31G is the best method to describe the most stable ketorolac structure. Docking studies have been performed on AutoDock and Gaussian software. Molecular docking results were used to predict the separation of ketorolac enantiomers in the AGP (alpha-1-acid-glycoprotein) chiral column by comparing the binding energies and types of interaction. To ensure the accuracy of the results, not only specific docking was performed, but blind docking was also conducted in this study. The results of the study show that the binding energy of S-ketorolac is more negative than that of R-ketorolac, indicating that stronger interaction between S-ketorolac and AGP occurs. Therefore, the R-ketorolac will be eluted first from the AGP column followed by S-ketorolac. As expected, this prediction is in good agreement with the experimental results of the separation of ketorolac enantiomers.
APA, Harvard, Vancouver, ISO, and other styles
2

Fernandes, V., F. S. Regateiro, J. P. Baptista, T. M. Alfaro, and M. J. Matos. "Severe ketorolac-induced asthma diagnosed by chest CT." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tiwari, Chhitij, Aaron Gelinne, Nathan Quig, Brian Thorp, Adam Zanation, Matthew Ewend, Diana Sasaki-Adams, and Carolyn Quinsey. "Ketorolac Administration Reduces Opioid Usage in Postoperative Pituitary Adenoma Patients." In Special Virtual Symposium of the North American Skull Base Society. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1725368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hermawan, Dadan, Cacu Cacu, Amin Fatoni, Suwandri, Wan Aini Wan Ibrahim, and Hassan Y. Aboul-Enein. "Development of Ketorolac Analysis in Water Samples using Micellar Electrokinetic Chromatography." In Soedirman International Conference on Mathematics and Applied Sciences (SICOMAS 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/apr.k.220503.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ghosalkar, Jeevan Deepak, Siddhika Rajiv Raut, Mariamma Charles Thekkumpurath, Geena Malhotra, and Kalpana Sanjay Joshi. "Abstract B141: Repurposing of ketorolac for the treatment of renal cell carcinoma (RCC)." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1535-7163.targ-17-b141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Luyckx, M., C. Verougstraete, P. Forget, M. Jouret, M. Waterkeyn, F. Grandjean, J.-F. Baurain, J.-P. Van Gossum, and J. Squifflet. "EP909 Influence of intraoperative administration of ketorolac on the prognosis of ovarian cancer." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Imani, F., P. Rahimzadeh, HR Faiz, S. Nowruzina, A. Shakeri, and M. Ghahremani. "ESRA19-0576 Comparison of the post-caesarean analgesic effects of adding dexmedetomidine to paracetamol and ketorolac." In Abstracts of the European Society of Regional Anesthesia, September 11–14, 2019. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/rapm-2019-esraabs2019.145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kenney, Shelby R., Tudor Oprea, Oleg Ursu, Larry Sklar, Lesley Lomo, Carolyn Muller, Yuna Gao, Angela Wandinger-Ness, and Laurie Hudson. "Abstract 910: Selective inhibition of Rac1 and Cdc42 in ovarian cancer using the R-enantiomer of ketorolac." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-910.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ali, Maimoona, and James Davies. "46 Service evaluation of the use of ketorolac at the macmillan palliative care unit (MPCU), Sheffield 2018–2019." In Accepted Oral and Poster Abstract Submissions, The Palliative Care Congress 1 Specialty: 3 Settings – home, hospice, hospital 25 – 26 March 2021 | A virtual event, hosted by Make it Edinburgh Live, the Edinburgh International Conference Centre’s hybrid event platform. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/spcare-2021-pcc.64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Freitas-Junior, R., R. Freitas-Junior, L. Silveira-Junior, W. Tokaski, C. Ximenes, R. Rahal, A. Santos, M. Tomazini, E. Martins, and N. Freitas. "Randomized Double-Blind Placebo-Controlled Clinical Trial Testing Ketorolac Tromethamine for Reducing the Pain and Discomfort Experienced during Mammography." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4014.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Ketorolac"

1

Hutton, Stephen B. Preoperative Use of lntranasal Ketorolac Tromethamine (Sprix) in Periodontal Flap Surgery. Fort Belvoir, VA: Defense Technical Information Center, May 2015. http://dx.doi.org/10.21236/ad1012707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Halker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah, et al. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer239.

Full text
Abstract:
Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ketorolac' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography